Interferon beta-1a biosimilar (Probiomed S.A)

干扰素β-1a生物类似药 (Probiomed S.A)

Report date: 2022/02/21 11:10:10

Base Information

Drug NameInterferon beta-1a biosimilar (Probiomed S.A)
Drug Alias NameEmaxem干扰素β-1a生物仿制药 (Probiomed S.A)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMexico
Original Approved Date2006/03/01
Country/TerritoryMexico
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesProbiomed
China Registration ClassN/A

Develop Information

Active CompaniesProbiomed
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeL03AB07
Related LinksN/A